Talphera (TLPH) Competitors

Talphera has higher revenue and earnings than Nkarta. Talphera is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 9.8% of Nkarta shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nkarta had 3 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Nkarta and 0 mentions for Talphera. Nkarta's average media sentiment score of 0.59 beat Talphera's score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Nkarta presently has a consensus target price of $10.75, indicating a potential upside of 318.29%. Talphera has a consensus target price of $3.00, indicating a potential upside of 132.56%. Given Nkarta's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nkarta is more favorable than Talphera.

Nkarta has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Talphera has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Nkarta's return on equity of -30.90% beat Talphera's return on equity.

In the previous week, Artiva Biotherapeutics had 6 more articles in the media than Talphera. MarketBeat recorded 6 mentions for Artiva Biotherapeutics and 0 mentions for Talphera. Artiva Biotherapeutics' average media sentiment score of 1.61 beat Talphera's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

37.7% of Talphera shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Artiva Biotherapeutics' return on equity of -73.15% beat Talphera's return on equity.

Talphera has lower revenue, but higher earnings than Artiva Biotherapeutics. Talphera is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 326.23%. Talphera has a consensus price target of $3.00, indicating a potential upside of 132.56%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Artiva Biotherapeutics is more favorable than Talphera.

Artiva Biotherapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Talphera has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

In the previous week, Talphera's average media sentiment score of 0.00 equaled I-Mab'saverage media sentiment score.

37.7% of Talphera shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Talphera has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

I-Mab's return on equity of 0.00% beat Talphera's return on equity.

Talphera presently has a consensus target price of $3.00, indicating a potential upside of 132.56%. I-Mab has a consensus target price of $9.00, indicating a potential upside of 402.79%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Talphera.

Talphera has higher earnings, but lower revenue than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Talphera has higher revenue and earnings than Protara Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

37.7% of Talphera shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Protara Therapeutics' return on equity of -38.70% beat Talphera's return on equity.

Talphera has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Talphera currently has a consensus price target of $3.00, suggesting a potential upside of 132.56%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 544.96%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Talphera.

In the previous week, Talphera's average media sentiment score of 0.00 equaled Protara Therapeutics'average media sentiment score.